Modulation of DNA damage response and induction of apoptosis mediates synergism between doxorubicin and a new imidazopyridine derivative in breast and lung cancer cells

•A new compound (IAZP) identified that has weak anticancer activity alone.•Its combination with doxorubicin resulted in synergism in breast/lung cancer cells.•Synergism is due to modulation of DNA damage response and induction of apoptosis.•IAZP enhances effects of doxorubicin on capsases, p21, CDK2...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	DNA repair 2016-01, Vol.37, p.1-11
Hauptverfasser:	El-Awady, Raafat A., Semreen, Mohammad H., Saber-Ayad, Maha M., Cyprian, Farhan, Menon, Varsha, Al-Tel, Taleb H.
Format:	Artikel
Sprache:	eng
Schlagworte:	Antineoplastic Combined Chemotherapy Protocols - pharmacology Antineoplastic Combined Chemotherapy Protocols - therapeutic use Apoptosis Apoptosis - drug effects Ataxia Telangiectasia Mutated Proteins - drug effects Ataxia Telangiectasia Mutated Proteins - metabolism Benzimidazoles - therapeutic use Breast Neoplasms - drug therapy Cell Line, Tumor Cell Proliferation - drug effects Cyclin-dependent kinase (CDK) DNA - drug effects DNA - metabolism DNA Damage DNA damage response DNA Repair - drug effects Doxorubicin Doxorubicin - pharmacology Doxorubicin - therapeutic use Drug discovery Female Humans Lung Neoplasms - drug therapy p21 Phosphorylation Pyridines - therapeutic use
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!